Back to search results
NCT05131594

Evaluating the Response of the Immune System of People with Long COVID (post SARS-CoV-2)

Enrolling by Invitation
Not specifiedAges 18+Observational
Huntington Memorial Hospital
~100 participants
Updated 2024-09-19 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Correlation of symptomatology with inflammatory profiles in patients with Post-Acute Sequelae of SARS-CoV2 (PASC)
Measured over From onset of infection to 24 months
+4 more outcomes measured

Conditions

COVID-19

Explore related trials

Post-Acute Sequelae of COVID-19Post-acute sequelae of SARS-CoV2

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Kimberly Shriner, MD · PRINCIPAL_INVESTIGATOR · Huntington Hospital

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Enrolled in Huntington Hospital\'s Long Covid Recovery Clinic
Documented previous infection with SARS-CoV2
Symptoms suggestive of post-acute sequelae of SARS-CoV2 (including but not limited to chronic fatigue, brain fog, muscle and joint pain, cardiac and pulmonary issues, or other factors related to their acute COVID-19 event)
Signed Informed Consent Form

Exclusion

No documented positive SARS-CoV2 serologies
No post-acute sequelae of SARS-CoV2 symptomatology
Incarcerated

What this trial measures

  • Correlation of symptomatology with inflammatory profiles in patients with Post-Acute Sequelae of SARS-CoV2 (PASC)From onset of infection to 24 months

    Do patient symptoms correlate with abnormalities in inflammatory profiles?

  • Identification of immunologic and inflammatory features of PASC based on results of immunologic and inflammatory assaysFrom onset of infection to 24 months

    Are there abnormalities in immunologic and inflammatory assays unique to PASC?

  • Evaluation and delineation of the pathologic pathways and long-term effects of SARS-CoV2 infectionFrom onset of infection to 60 months

    What are the pathological pathways and long-term effects of SARS-CoV2?

  • Identification of risks factor for PASCFrom onset of infection to 24 months

    What are the risk factors for PASC?

  • Identification of potential sites of therapeutic intervention to ameliorate symptomatology of PASCFrom onset of infection to 60 months

    Are there potential sites of therapeutic intervention to relieve the symptoms of PASC?